(Press-News.org) This news release is available in Spanish.
Bacterial resistance to drugs leads pharmaceutical labs to be in constant search for new antibiotics to treat the same diseases. For the last thirty years, the sea bottom has yielded a wealth of substances with properties of interest to the pharmaceutical industry. Isolated from a marine microorganism off the coast of Alicante by the company BioMar, baringolin shows promising antibiotic activity at a very low concentration. The Combinatorial Lab headed by Fernando Albericio at the Institute for Research in Biomedicine (IRB Barcelona), which collaborates with BioMar, has now synthesized this molecule and revealed its structure. Today's results open up the possibility to better understand how this substance works and to design derivatives to turn into a viable drug in the next 10 years. These findings are advanced in todays' online edition of Angewandte Chemie, the scientific journal of reference in chemistry.
The researcher Xavier Just-Baringo, who is doing his PhD in the Combinatorial Chemistry Lab, has spent the last four years studying the structural composition of baringolin and has reconstructed this molecule in the lab as if it were 3D a puzzle of atoms that can be joined up in many ways. "This substance has 128 possible structural configurations but only one is an exact replica of the natural peptide. We have been able to find it via 39 synthesis steps," explains Just-Baringo who has had the privilege to name the new compound.
The researchers have finely tuned the organic synthesis of the natural peptide and several analogues and will address the biological activity of these molecules and attempt to improve their pharmacological and pharmacokinetic properties. Through collaboration with the Department of Pharmacology at the Hospital Clínic de Barcelona, they will test the analogues against several strains of gram-positive bacteria, one of the two large groups into which bacteria are classified and against which baringolin has shown inhibitory activity.
Thiopeptides: a new family of antibiotics
Structurally speaking, baringolin is a thiopeptide. These molecules are a new family of antibacterial agents of terrestrial and marine origin, and about 100 have been identified to date. "There is only one thiopeptide on the market for the treatment of bacterial infections, thiostrepton (Panolog), and it is used in veterinary medicine for skin infections. Nothing is available for humans yet," explanis Mercedes Álvarez, associate researcher in the lab, senior professor at the University of Barcelona (UB), and supervisor of the study. The main drawback of thiopeptides is that they show low solubility. For baringolin to be viable as a drug, its solubility must be improved because antibiotics are administered orally or intravenously. "Using the analogues, we aim to improve this feature and identify the parts of the molecule responsible for their antibiotic activity in order to be able to design new more active and smaller analogues," says Álvarez.
"We have taken the first step towards achieving a future drug," says Albericio. "Along the way we have learnt how to synthesize natural molecules and have developed new methods," adds the head of the group and senior professor at the UB. The final objective of the lab is to achieve the total synthesis of natural substances, the last two of which have been thiocoralin, an antitumoral agent that belongs to PharmaMar, and baringolin, belonging to BioMar. "The synthesis of natural products in the lab has a double justification. One is environmental, to protect species that hold substances of pharmacological interest, and the other is commercial, as manufacturing a drug on a large scale is viable only if its production can be ensured on an industrial scale," explain the researchers.
INFORMATION:
Reference article:
Total Synthesis and Stereochemical Assignment of Baringolin
Xavier Just-Baringo, Paolo Bruno, Lars K. Ottesen, Librada M. Cañedo, Fernando Albericio and Mercedes Álvarez.
Angewandte Chemie (2013) http://dx.doi.org/10.1002/ange.201302372 (German Edition)
http://dx.doi.org/10.1002/anie.201302372 (International Edition)
Lab reproduction of a marine compound with antibiotic properties
2013-06-20
ELSE PRESS RELEASES FROM THIS DATE:
Too green to be true? Researchers develop highly effective method for converting CO2 into methanol
2013-06-20
Quebec City, June 20, 2013—Université Laval researchers have developed a highly effective method for converting CO2 into methanol, which can be used as a low-emissions fuel for vehicles. The team led by Professor Frédéric-Georges Fontaine presents the details of this discovery in the latest issue of the Journal of the American Chemical Society.
Researchers have been looking for a way to convert carbon dioxide into methanol in a single step using energy-efficient processes for years. "In the presence of oxygen, methanol combustion produces CO2 and water," explained Professor ...
American Chemical Society global program tackles safe drinking water in Colombia
2013-06-20
The Global Innovation Imperatives (Gii) program, administered by the American Chemical Society (ACS) Office of International Activities, today issued a white paper outlining possible solutions for increasing access to safe drinking water in the rural areas of the world. Although focused on the community of Chocontá, in Colombia, the suggested solutions have broader application.
Chocontá residents rely on rural aqueducts for their water, but supplies are vulnerable to pollution from nearby agriculture and largely go untreated. City officials asked ACS, the world's largest ...
'Forrest Gump' mice show too much of a good thing, can be bad
2013-06-20
VIDEO:
This video shows a control mouse doing a task to test cognitive skills. The mouse must start the test, then scan and touch the screen at the spot where...
Click here for more information.
A line of genetically modified mice that Western University scientists call "Forrest Gump" because, like the movie character, they can run far but they aren't smart, is furthering the understanding of a key neurotransmitter called acetylcholine (ACh). Marco Prado and his team at Robarts ...
Rhode Island Hospital reduces incidence of hospital-associated C. difficile by 70 percent
2013-06-20
PROVIDENCE, R.I. – Rhode Island Hospital has reduced the incidence of hospital-associated Clostridium difficile (C. difficile) infections by 70 percent and reduced annual associated mortality in patients with hospital-associated C. difficile by 64 percent through successive implementation of five rigorous interventions , as reported in the July 2013 issue of The Joint Commission Journal on Quality and Patient Safety.
Clostridium difficile is a toxin-producing bacterium that lives in the colon. A major cause of morbidity and mortality in the U.S., it can cause life-threatening ...
Virus combination effective against deadly brain tumor, Moffitt Cancer Center study shows
2013-06-20
A combination of the myxoma virus and the immune suppressant rapamycin can kill glioblastoma multiforme, the most common and deadliest malignant brain tumor, according to Moffitt Cancer Center research. Peter A. Forsyth, M.D., of Moffitt's Neuro-Oncology Program, says the combination has been shown to infect and kill both brain cancer stem cells and differentiated compartments of glioblastoma multiforme.
The finding means that barriers to treating the disease, such as resistance to the drug temozolomide, may be overcome. The study, by Forsyth and colleagues in Canada, ...
Making a beeline for the nectar
2013-06-20
Bumblebees searching for nectar go for signposts on flowers rather than the bull's eye. A new study, by Levente Orbán and Catherine Plowright from the University of Ottawa in Canada, shows that the markings at the center of a flower are not as important as the markings that will direct the bees to the center. The work is published online in Springer's journal, Naturwissenschaften - The Science of Nature.
The first time bees go out looking for nectar, which visual stimuli do they use to identify that first flower that will provide them with the reward they are looking ...
Scientists design a potential drug compound that attacks Parkinson's disease on 2 fronts
2013-06-20
JUPITER, FL-- Scientists from the Florida campus of The Scripps Research Institute (TSRI) have found a compound that could counter Parkinson's disease in two ways at once.
In a new study published recently online ahead of print by the journal ACS Chemical Biology, the scientists describe a "dual inhibitor"- two compounds in a single molecule-- that attacks a pair of proteins closely associated with development of Parkinson's disease.
"In general, these two enzymes amplify the effect of each other," said team leader Phil LoGrasso, a TSRI professor who has been a pioneer ...
Total amount of exercise important, not frequency, research shows
2013-06-20
A new study by Queen's University researchers has determined that adults who accumulated 150 minutes of exercise on a few days of the week were not any less healthy than adults who exercised more frequently throughout the week.
Ian Janssen and his graduate student Janine Clarke studied 2,324 adults from across Canada to determine whether the frequency of physical activity throughout the week is associated with risk factors for diabetes, heart disease and stroke.
"The findings indicate that it does not matter how adults choose to accumulate their 150 weekly minutes of ...
Goal of identifying nearly all genetic causes of deafness is within reach
2013-06-20
New Rochelle, NY, June 20, 2013—At least half of all cases of deafness that develop from birth through infancy in developed countries have a genetic basis, as do many cases of later onset progressive hearing loss. To date, at least 1,000 mutations occurring in 64 genes in the human genome have been linked to hearing loss. Next-generation DNA sequencing technologies are enabling the identification of these deafness-causing genetic variants, as described in a Review article in Genetic Testing and Molecular Biomarkers, a peer-reviewed journal from Mary Ann Liebert, Inc., publishers. ...
African-Americans on Medicaid are far less likely to receive living kidney transplants
2013-06-20
WINSTON-SALEM, N.C. – June 20, 2013 – African-Americans with Medicaid as their primary insurance were less likely to receive a living kidney transplant (LKT) than patients with private insurance, according to a new study by researchers at Wake Forest Baptist Medical Center.
The study is published on the Early View online edition of Clinical Transplantation.
"Living kidney transplantation is the optimal treatment for patients with end-stage renal disease, offering the best quality of life and longest survival," said Amber Reeves-Daniel, D.O., assistant professor of nephrology ...